CYP19A1 and breast carcinoma: Higher AR expression in ER-positive breast cancers is generally correlated with better clinical outcomes and a favorable response to endocrine therapies, such as selective estrogen receptor modulators (SERMs) and aromatase inhibitors [101,123].